Recent

% | $
Quotes you view appear here for quick access.

Alnylam Pharmaceuticals, Inc. Message Board

SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • I'm totally blown away. A few guys were bragging about their winnings on the yahoo message boards, so I decided to go to the 'Penny Stock 101' website (just google or yahoo search for it) and signed up to their email newsletter. (There is no charge to become a member) Their last 6 NASDAQ-listed winners in this Fall 2015 season ran for +33%, +45%, +58%, +64% +72%, and +116% gains. Do yourself a favor and get to that website right now, and become a member. I guarantee u will thank me later.

  • Reply to

    HPV B

    by gswkool Feb 14, 2016 11:52 AM

    ALNY was my best short ever

  • so much selling?? looks like a steal at these levels

  • off the reservation again!!!!

    Last seen telling us what a genius JM was letting Roche and Novartis get away, keeping his cash in a CD for security.

    You might need the straight jacket.

  • Reply to

    All Points Bulletin....NotForRookies

    by marcpuckett Mar 14, 2016 12:29 PM

    No really. Here is what they are saying about him at ARWR's board

    nfr
    You are truly brilliant.

    JM did a wonderful job trying to compete with ARWR to acquire the Roche and NVS DPC/RNAi assets. He really ate Dr. A as an appetizer on those fronts. You sure do know what you are talking about. You are right all the time about everything. Everyone should listen to you because you have it right all the time. Nobody smarter than you. JM sure is a tough guy. He told Dr Lewis that nobody is going to tell him what to do with a company and its employees once he acquires it and that tough guy tactic sure worked well. Yep. The tough guy is tough guying himself right into the shyter. Genius tough guy. NVS RNAi assets worthless. Genius tough guy. Every major pharmaceutical partnership ALNY has had has been blown apart at the seams by the genius tough guy. Jury is still out on Genzyme but that one will likely go down the shyter just like MRK, NVS, Schering and Roche. He is such a genius tough guy that his own employees hate him. Half his chemists have defected to ARWR because he is such a genius tough guy. You gotta love JM. He is such a genius tough guy. God bless JM the genius tough guy.

    All hail the brilliant nfr and JM the genius tough guy. (by holdencf, one of our best batters!)

  • I've been following trade alerts from the Penny Stock 101 org newsletter, and I've been consistanly beating the market. If you want to get an early jump on the fastest moving NASDAQ, NYES and OTC stocks signup now.Just on an email stating they have a new pick coming tomorrow!

  • Vist their site and Sign up to TOP MARKET GAINERS dot com (just enter the url in your browser) and watch their next few plays. I have been impressed so far.

  • Alnylam's pipeline has not delivered its promises in the last 10 years.

    Investment banks' analysts in a situation of conflict of interest seem to overvalue it.

    ALNY is no more than a pharma company focused on a particular orphan disease with strong competitors.

    A rigorous valuation of the company makes its stock worth less than $45.

  • Are you advising others to short this stock?
    How about you, have you shorted this stock?
    You present your short position,
    and I'll present my position.
    Fair enough?
    nt

  • Reply to

    Why You Should Short Alnylam

    by tnorman200 Apr 3, 2016 6:34 PM

    tnorman
    I'll bite on that one. Starts with the CEO. He is a liar and an arZehole. He has blown up every major pharma relationship he has closed with the exception of Genzyme which is relatively new. The pharma relationships have blown up because he lied to all of them about his delivery capability. He walked away with their money and they got virtually nothing. He has bought four delivery platforms and not one of them has worked. He licensed ARWR's DPCs and then went on to pizz them off by making publicly derogatory comments about ARWR's acquisition of Roche and NVS RNAi assets. So he has an unfinished v.1.0 version of DPCs and he hasn't been able to make them work. In response, he is using GalNAcs which are unstable and thus cause toxicity below a certain size. Apparently he has figured out a way to stabilize them at smaller sizes with a tighter binding agent that tamps down cellular uptake. In July 2015 he talked a big game at an HBV round table and forced his scientist to make comments about their program (and ARWR's) that clearly the scientist was not comfortable with. He also said HBV IND by YE15. Then without another word, in Jan 16 they pushed their IND filing date to mid-2016. They called it a manufacturing problem. But it doesn't take 6 months total to scale up GMP for a new drug. Have heard nothing about ALN-AAT. My guess is that they had enrollment problems but they might have had delivery problems as well since that has been a broader systemic problem. There are also questions about whether or not ALNY own its GalNAc technology as a paper and IP were written and filed by David Rozema that predates ALNY's purchase of Sirna from MRK. I am not sure about this last comment but I have seen some evidence to that effect.

    There are other bits and pieces. Have lost a lot of scientists. Lots of dead patients, etc.... Cheerily awaiting your response.

    Full disclosure. I have been short ALNY but am not now.

  • Reply to

    Why You Should Short Alnylam

    by tnorman200 Apr 3, 2016 6:34 PM

    as far as I'm concerned,
    this is all hearsay.
    What matters to me is that ALNY has NEVER been downgraded by a single analyst.
    And the shares have acted well of late.
    Still, you have NO short position. You're not putting any money in support of
    your numerous claims.
    'nt

  • Reply to

    Why You Should Short Alnylam

    by tnorman200 Apr 3, 2016 6:34 PM

    Further, if you take a quick look at the
    analyst recommendations on Yahoo,
    not a single "sell."
    In fact, almost all have strong "buys."
    You're suggesting you know something they don't.
    That's pretty common on message boards.
    Good luck
    nt

  • Reply to

    Why You Should Short Alnylam

    by tnorman200 Apr 3, 2016 6:34 PM

    You sound like a moron!!! who believe the analysts cheerleaders, btw their average target price is $180 go figure may be ur grand children can cash out at $20.00 in 50 years

  • but I should take advice from a fakir like you.
    Is that right?
    By the way, the shares were up pretty strong today.
    Does that mean you're considering shorting the shares again?
    nt

  • My PT $7 $7 $7

    Short it and make some real $$$$$$$$$$7

    Sentiment: Strong Sell

  • I've tried them all. Every newsletter in the business. Penny Stock 101 (org) is the only one that lives up to thge hype. They have the best NASDAQ, NYSE and OTCMarket alerts. Google them, sign up for their newsletter (it's no charge). You won't regret it!

  • Reply to

    Why You Should Short Alnylam

    by tnorman200 Apr 3, 2016 6:34 PM

    tnorman
    i don't much give a #$%$ what you think. What is hear say about every major pharma relationship blowing upon ALNY? You can research everything I talked about in my post. Some of it is opinion which I try to make clear. As for sell side analysts, they work for investment banks. Investment banks make their money issuing shares, not trading them. Analysts have to keep issuers happy so bankers let them keep their jobs and pay them bonuses. How can I say this with such certitude? I used to be an analyst...for 10 years before I moved to the buy side before I became a banker.

    For the record I said I don't have a position NOW!!! I have traded this stock many times. It's a cash register. I have never been long because I don't buy stock in companies with dishonest, shi##y management. I have been following this company since shortly after it went public. The biotech analyst at my firm had a buy on it because he was just paid a $1.2 bonus because of the IPO fee. He pointed out one immutable fact that ALNY has yet to overcome in a meaningful way. They also filed their IP after a man named David Rozema filed his GalNAc IP when he was at Roche. ALNY's first GalNAc filing was done by a Dr. Matsueda. Is that hearsay? Look it up. It's all out there to be had.

    One day this stock is going to blow all to he!!. Until then, every major run it makes I will short. Question about these "smart" analysts...Didn't they all have buy ratings on the stock when it peaked at $140...just before it dropped over 80 pts, a decline of roughly 60%? How smart are they again? Very smart bc their slave masters, the bankers, keep paying them to outwardly trumpet the name. I bet the conversations analysts have with Fidelity, Wellington and Wasatch behind the scenes sounds a bit different. Enjoy the ride. I sure will.

Must Watch
ALNY
57.81+1.74(+3.10%)May 24 4:00 PMEDT